Chen R, et al. – Researchers gauged the efficacy and prognostic factors of bortezomib and dexamethasone (BD) chemotherapy regimen in the treatment of newly diagnosed multiple myeloma (MM) patients in the hospital. For this group of patients, BD regimen was effective and well tolerated. Level of albumin, plasma cell percentage in bone marrow, β2–microglobulin and cytogenetic abnormalities were prognostic factors for patients’ survival.